Heidelberg Pharma AG

AGM Information • Jun 13, 2007

News Details

Corporate | 13 June 2007 10:02

WILEX AG: Annual General Meeting appoints new Supervisory Board members

WILEX AG / AGM/EGM

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Annual General Meeting appoints new Supervisory Board members

Munich, 13 June 2007. The Annual General Meeting of the Munich-based
biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock
Exchange/Prime Standard) yesterday appointed two new members to its
Supervisory Board: Professor Iris Löw-Friedrich, Executive Board member
responsible for Research and Development at SCHWARZ PHARMA AG and Dr.
Rüdiger Hauffe, Consultant and former CEO of SmithKline Beecham GmbH,
Germany.

Dr. David Ebsworth, Dr. Georg Baur, Dr. Alexandra Goll and Dr. Friedrich
von Bohlen und Halbach were reappointed to the Company's Supervisory Board.
Dr. David Ebsworth was elected chairman and Dr. Georg Baur as deputy
chairman of the board in the supervisory board meeting which followed the
Annual General Meeting.

Professor Olaf G. Wilhelm, CEO of WILEX AG commented: 'We have gained with
Professor Löw-Friedrich a renowned expert in drug development who will make
a significant contribution in the supervisory board. Dr. Hauffe has
significantly contributed to the marketing skills of various pharmaceutical
and biotechnology companies. His expertise will be of enormous support to
us as we focus our efforts on the commercialisation of our products in the
near future. We would like to thank both new members for joining the
Supervisory Board of WILEX.'

The Company also extends its thanks to the former Supervisory Board
members, Dr. Jeremy Reffin of Apax Partners and Salvatore D’Orsa of Merlin
Biosciences, who did not stand for re-election as neither Apax Partners or
Merlin allows its employees to serve on the Supervisory Board of a listed
company.

About WILEX
WILEX is a biopharmaceutical Company based in Munich, which was founded in
1997 by a team of physicians and oncologists from the Technical University
of Munich. WILEX is focused on the development of new cancer therapies
based on antibodies and small molecules. The therapeutic approach of WILEX
targets the prevention of growth, spread and the metastasis of malignant
tumours and the destruction of malignant tumours in the body. The portfolio
includes both drug and medical product candidates ranging from research to
late stage clinical development. Currently the following compounds are in
clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1
and CA9-SCAN. The company's strategy is to develop WILEX into a
commercially successful biopharmaceutical company with a broad portfolio of
new drugs and medical products for the treatment of cancer. Since 13
November 2006, WILEX AG has been listed on the Frankfurt Stock Exchange in
the Official Market Segment/Prime Standard. (ISIN DE0006614720/WKN
661472/Stock market symbol WL6).

DGAP 13.06.2007

Language: English
Issuer: WILEX AG
Grillparzerstr. 16
81675 München Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
www: www.wilex.de
ISIN: DE0006614720
WKN: 661472
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---